🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

HOPE, es esperanza pero es también pacientes activas y formadas + oncología personalizada y de precisión Es tiempo para el #cáncermamametástasico 👏🏻👏🏻👏🏻

Wonderful team, wonderful science! #BeSolti SOLTI #cancerresearch SABCS OncoAlert

So grateful for the privilege of being part of this exceptional group!🙌🏼 Tomás Pascual Mafalda Oliveira Eva M Ciruelos Maria Vidal Juanmi Cejalvo Rodrigo Sánchez-Bayona Guillermo Villacampa Meritxell Bellet Cristina Saura Cristina Hernando Milana Bergamino Sirven Juan M. Ferrero-Cafiero Fara Brasó Maristany Montserrat Muñoz Mateu Sonia Pernas

💪

May our projects sprout, grow, and bloom as a symbol of shared life hope 🌿🧬 SOLTI #cancerresearch #BeSOLTI

La supervivencia del cáncer en España se ha DUPLICADO en los últimos 40 años. Esa debe ser la noticia de este lunes 29 de enero. SEOM

You have to be willing to be a fool to advance. When you're learning anything new, you'll feel like an imposter. That's a very useful thing to know. You'll feel like a fool because you are. And you'll think, “I'll never get there”. The destination might look very distant, but

Nace SOLTIyoung, una apuesta entusiasta y firme de SOLTI #cancerresearch para el futuro… Stay tuned! 🙌🏻👀👀

#whatwedoisimportant

🔬 Excited to share our latest research published in npj Journals , where we explored the effects of cell-cycle inhibition and the immune microenvironment in breast cancer treated with ribociclib and letrozole vs. chemotherapy. A thread 🧵 nature.com/articles/s4152…

📢Primera paciente incluida en el estudio ACROSS-TROP2! Análisis prospectivo de biomarcadores en pacientes con #cancerdemama metastásico o avanzado HR+/HER2- tratadas con sacituzumab govitecan 🔗gruposolti.org/ensayosclinico… 👩‍⚕️👩‍⚕️IPs Mafalda Oliveira Eva M Ciruelos #beSOLTI

Less than 48h to #ESMOBreast24: time for the #top10 abstracts. Highly awaited readout from IMp132, safety update of important ph 3 trials (TB01, NATALEE), intriguing biomarker analyses from large datasets (HER2DX, monarchE) and much more. Promises to be a terrific congress! #bcsm

Super excited to share our work, this thread is a must read if you are looking for insights on how we might be selecting ADC in this complex and evolving landscape. biomarkers, biomarkers, biomarkers!

Explicación breve para un extranjero (o venezolano) que no sabe muy bien lo que está pasando en el país x.com/picosuarez/sta…

What is the impact of immune checkpoint inhibitors in the outcome of patients with early breast cancer? Check out this huge work led by Guillermo Villacampa and Tomás Pascual Treatment tailoring is paramount to improve patient care! ESMO - Eur. Oncology OncoAlert Vall d’Hebron Institute of Oncology (VHIO) ASCO